OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
2506$76.1558

Xunfei Healthcare Technology Co Ltd

Advanced Medical Equipment & TechnologyVerified

The company's capital structure shows a debt-to-equity ratio of 0.32, indicating a relatively conservative leverage position. However, the liquidity position is constrained, with negative free cash flow of -103.45 million CNY and operating cash flow of -42.97 million CNY. The current ratio of 1.41 suggests the company has sufficient short-term assets to cover its liabilities, but the negative net cash position after subtracting total debt raises concerns about its ability to fund operations without external financing. Profitability metrics are weak, with a return on equity of -7.23% and a return on assets of -2.8%. The company reported a net loss of 64.79 million CNY and an operating loss of 81.69 million CNY, indicating significant challenges in achieving profitability. Gross profit of 461.64 million CNY on revenue of 914.99 million CNY suggests a gross margin of approximately 50.45%, which is relatively high but insufficient to offset operating expenses. The company's revenue is concentrated in a single geographic market, primarily China, with no disclosed international operations. This concentration increases exposure to local economic and regulatory risks. The company operates in a single business segment focused on healthcare equipment and technology, with no material diversification across product lines or customer bases. The company's growth trajectory is uncertain, with no disclosed revenue growth in the most recent period. Analysts have set a mean price target of 102.17 CNY, implying a potential upside of 34.2% from the current market price of 76.15 CNY. However, the company's negative operating and free cash flows suggest that achieving this growth may require significant capital investment or operational improvements. Risk factors include liquidity constraints, with negative free cash flow and operating cash flow, and the potential for dilution if the company needs to raise additional capital. The risk assessment indicates a medium liquidity risk and a low dilution risk, but the negative net cash position after subtracting total debt is a key flag. Recent events include the publication of the latest financial results, which show continued losses and negative cash flows. There are no recent filings or transcripts indicating significant changes in strategy or operations. The company's reliance on a single geographic market and the absence of disclosed international expansion efforts suggest that it may be vulnerable to local economic and regulatory shifts.

30-day price · 2506+7.65 (+11.2%)
Low$64.55High$81.80Close$76.15As of18 May, 00:00 UTC
Profile
CompanyXunfei Healthcare Technology Co Ltd
Ticker2506.HK
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryAdvanced Medical Equipment & Technology
AI analysis

Business. Xunfei Healthcare Technology Co Ltd develops and provides AI-powered healthcare solutions, including medical imaging and diagnostic tools, primarily serving the Chinese healthcare market.

Classification. The company is classified under the Healthcare sector, specifically in the Advanced Medical Equipment & Technology industry, with a confidence level of 0.92 based on verified market data.

The company's capital structure shows a debt-to-equity ratio of 0.32, indicating a relatively conservative leverage position. However, the liquidity position is constrained, with negative free cash flow of -103.45 million CNY and operating cash flow of -42.97 million CNY. The current ratio of 1.41 suggests the company has sufficient short-term assets to cover its liabilities, but the negative net cash position after subtracting total debt raises concerns about its ability to fund operations without external financing. Profitability metrics are weak, with a return on equity of -7.23% and a return on assets of -2.8%. The company reported a net loss of 64.79 million CNY and an operating loss of 81.69 million CNY, indicating significant challenges in achieving profitability. Gross profit of 461.64 million CNY on revenue of 914.99 million CNY suggests a gross margin of approximately 50.45%, which is relatively high but insufficient to offset operating expenses. The company's revenue is concentrated in a single geographic market, primarily China, with no disclosed international operations. This concentration increases exposure to local economic and regulatory risks. The company operates in a single business segment focused on healthcare equipment and technology, with no material diversification across product lines or customer bases. The company's growth trajectory is uncertain, with no disclosed revenue growth in the most recent period. Analysts have set a mean price target of 102.17 CNY, implying a potential upside of 34.2% from the current market price of 76.15 CNY. However, the company's negative operating and free cash flows suggest that achieving this growth may require significant capital investment or operational improvements. Risk factors include liquidity constraints, with negative free cash flow and operating cash flow, and the potential for dilution if the company needs to raise additional capital. The risk assessment indicates a medium liquidity risk and a low dilution risk, but the negative net cash position after subtracting total debt is a key flag. Recent events include the publication of the latest financial results, which show continued losses and negative cash flows. There are no recent filings or transcripts indicating significant changes in strategy or operations. The company's reliance on a single geographic market and the absence of disclosed international expansion efforts suggest that it may be vulnerable to local economic and regulatory shifts.
Key takeaways
  • The company has a high gross margin of approximately 50.45% but is unprofitable, with a net loss of 64.79 million CNY.
  • The debt-to-equity ratio of 0.32 indicates a relatively conservative capital structure, but the negative free cash flow of -103.45 million CNY raises liquidity concerns.
  • Analysts have set a mean price target of 102.17 CNY, implying a potential upside of 34.2% from the current market price.
  • The company's revenue is concentrated in a single geographic market, primarily China, increasing exposure to local economic and regulatory risks.
  • The company operates in a single business segment focused on healthcare equipment and technology, with no material diversification across product lines or customer bases.
  • --
  • # RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyCNY
Revenue$915.0M
Gross profit$461.6M
Operating income-$81.7M
Net income-$64.8M
R&D
SG&A
D&A
SBC
Operating cash flow-$43.0M
CapEx-$86.9M
Free cash flow-$103.5M
Total assets$2.31B
Total liabilities$1.42B
Total equity$896.6M
Cash & equivalents$123.6M
Long-term debt$283.0M
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0$915.0M-$81.7M-$64.8M-$103.5M
FY-1$734.0M-$165.9M-$132.6M-$122.7M
FY-2$556.1M-$185.7M-$144.8M-$148.8M
FY-3$471.9M-$243.5M-$189.4M-$169.4M
FY-4$372.5M-$108.1M-$83.7M-$81.0M
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0$2.31B$896.6M$123.6M
FY-1$2.09B$939.9M$676.8M
FY-2$1.24B$498.8M$142.5M
FY-3$1.03B$341.2M$163.0M
FY-4$1.01B$426.6M$434.2M
PeriodOCFCapExFCFSBC
FY0-$43.0M-$86.9M-$103.5M
FY-1-$134.1M-$33.0M-$122.7M
FY-2-$314.3M-$36.5M-$148.8M
FY-3-$113.9M-$15.1M-$169.4M
FY-4-$52.7M-$28.6M-$81.0M
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodOCFCapExFCFSBC
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
Valuation
Market price$76.15
Market cap$9.20B
Enterprise value$9.36B
P/E
Reported non-GAAP P/E
EV/Revenue10.2
EV/Op income
EV/OCF
P/B10.3
P/Tangible book10.3
Tangible book$896.6M
Net cash-$159.4M
Current ratio1.4
Debt/Equity0.3
ROA-2.8%
ROE-7.2%
Cash conversion66.0%
CapEx/Revenue-9.5%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Healthcare Equipment · cohort 160 companies
Metric2506Activity
Op margin-8.9%-24.0% medp25 -212.9% · p75 6.1%above median
Net margin-7.1%-20.7% medp25 -188.5% · p75 4.8%above median
Gross margin50.5%49.8% medp25 36.6% · p75 67.4%above median
CapEx / revenue-9.5%-4.7% medp25 -11.2% · p75 -1.8%below median
Debt / equity32.0%3.6% medp25 0.0% · p75 22.2%top quartile
Observations
IR observations
Mean price target102.17 CNY
Median price target102.17 CNY
High price target111.80 CNY
Low price target92.55 CNY
Mean recommendation1.67 (1=strong buy, 5=strong sell)
Strong-buy count1.00
Buy count2.00
Hold count0.00
Sell count0.00
Strong-sell count0.00
Mean EPS estimate-0.14 CNY
Last actual EPS-0.32 CNY
Source: analysis-pipeline (hybrid)Generated: 2026-05-19 01:25 UTCJob: 944b683c